References
- Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immune-compromised host. Am J Med 1981; 71: 363–370.
- Richardson K, Brammer KW, Marriott MS, Troke PF. Activity of UK-49,858, a bistriazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 1985; 27: 832–835.
- Brammer KW, Tarbit MH. A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man, In: R.A. Fromtling (Ed) Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, Barcelona JR. Prous; 1987; p 141.
- Brammer KW, Lees LJ. Single dose oral fluconazole in the treatment of vulvovaginal candidiasis: An interim analysis of a comparative study vs three-day intravaginal clotrimazole tablets. In: R.A. Fromtling (Ed) Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, Barcelona: J.R. Prous: 1987; 151.
- Shaw JTB, Tarbit MH, Troke PF. Cytochrome P-450 mediated sterol synthesis and metabolism: Differences in sensitivity to fluconazole and other azoles. In : R.A. Fromtling (Ed.) Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, Barcelona: JR Prous 1987; 125.